⚠️ When a Cold Is More Than a Cold
Certain health conditions put you at real risk for serious complications — here's what to know before you get sick
For most healthy adults, a cold is a miserable week that resolves on its own. But for people with certain underlying conditions, the same virus can trigger complications that are genuinely serious. If you or someone you care for falls into one of these groups, knowing the risks ahead of time — and knowing what to watch for — is the most useful thing I can offer.
Why some people are more vulnerable
The common cold becomes dangerous not because the virus itself is more aggressive, but because of how the body responds to it. In people with lung disease, the inflammatory response that a cold triggers can tip an already-stressed airway into crisis. In people with weakened immune systems, the infection that a healthy person clears in a week can spread into the lungs before the body gets it under control. In older adults, a less responsive immune system means the infection takes longer to contain and can cause more collateral damage.
Understanding which category applies to you — and what signals to watch for — is the difference between catching a complication early and ending up in the emergency department.
The high-risk groups
The airways of people with asthma are chronically inflamed and hyperreactive — they respond to triggers with exaggerated narrowing (bronchoconstriction) that can make breathing difficult. Cold viruses are among the most potent triggers there are.
Viral respiratory infections are responsible for approximately 80% of asthma attacks in adults. The risk isn't that people with asthma get colds more often — it's that when they do, the consequences can be significantly more severe.
- Increased use of your rescue inhaler beyond your usual baseline
- Wheezing or chest tightness that doesn't respond to a rescue inhaler within 15–20 minutes
- Waking at night due to breathing difficulty
- Peak flow readings dropping below your personal best
COPD is a condition in which the airways and air sacs of the lungs are permanently damaged — most often from long-term smoking — leaving patients with chronically reduced lung function (reduced FEV1 and airflow obstruction). People with COPD don't get colds more often than anyone else, but when they do, the consequences can be disproportionately severe. Each significant exacerbation is associated with a measurable, permanent step-down in lung function.
- Breathlessness noticeably worse than your usual baseline
- Mucus changing from clear or white to yellow or green, with increased volume
- Increased use of rescue medications beyond your normal pattern
- Difficulty completing sentences or normal daily activities due to breathlessness
This is the one situation in this series where I recommend a prescription medication. A Cochrane review found that 5-day courses of prednisone (40 mg daily) are as effective as 10–14 day courses for treatment failure, relapse, and lung function recovery — with fewer side effects. Emerging data adds nuance: patients with blood eosinophil counts ≥2% show greater improvement with corticosteroids, while those with lower counts may not benefit and could have better outcomes without them.
The strongest evidence for azithromycin in COPD is for preventing exacerbations in high-risk patients, not treating acute illness. The landmark Albert trial (n=1,142) showed daily azithromycin for 1 year reduced exacerbation rates from 1.83 to 1.48 per patient-year (RR 0.83, 95% CI 0.72–0.95) and extended the median time to first exacerbation from 174 to 266 days. If you're having frequent exacerbations, this is worth a specific conversation with your provider.
If you're undergoing chemotherapy, taking immunosuppressive medications (such as prednisone, methotrexate, biologics, or post-transplant medications), or have a condition that impairs immune function, your body may not be able to contain a viral infection to the upper respiratory tract. What starts as a cold can become a serious illness much more quickly.
- Any fever — even low-grade — as this is a more significant signal in immunocompromised patients
- Symptoms that seem unusually severe or prolonged from the start
- Any cough that develops into chest symptoms — shortness of breath, chest pain, or colored mucus
The immune system becomes less responsive with age (immunosenescence) — slower to mount a response, slower to clear an infection, and more prone to collateral damage in the process.
Studies have found that approximately two-thirds of older adults who develop a cold experience lower respiratory symptoms, compared to a much smaller proportion in younger, healthy adults.
- Symptoms lasting significantly longer than 10 days without improvement
- Any chest symptoms developing — cough producing colored mucus, shortness of breath, chest discomfort
- Confusion or sudden changes in mental status, which can signal spreading infection
Acute viral illness places real physiological stress on the body — elevated heart rate, increased metabolic demand, inflammatory signaling throughout the body. For people with cardiovascular disease, this can strain a heart with limited reserve. For people with diabetes, the stress response can destabilize blood sugar control.
- Heart disease: chest pain, palpitations, or shortness of breath beyond what you'd expect from a cold
- Diabetes: blood sugars running significantly higher than your usual range, or difficulty keeping fluids down
- Both groups: any symptom that feels disproportionate to a typical cold
The most effective intervention: vaccination
Everything above applies once a cold or respiratory illness has started. But for high-risk patients, the most powerful tool available is vaccination — specifically against RSV and pneumococcal pneumonia.
RSV vaccination
A 2026 meta-analysis found RSV vaccines reduced RSV-related hospitalizations by 77% (OR 0.23, 95% CI 0.20–0.27) and emergency department visits by 77%. Effectiveness against critical illness was 81%. In immunocompromised adults, effectiveness was somewhat lower but remained substantial: a 70–73% reduction in RSV-associated hospitalization. The 2025 IDSA guidelines issued a strong recommendation for RSV vaccination in immunocompromised adults.
Current ACIP recommendations: RSV vaccination for all adults ≥75, and adults 60–74 with chronic heart/lung disease, immunocompromising conditions, or nursing home residency. The 2026 GOLD guidelines extend this to adults ≥50 with chronic heart or lung disease.
Pneumococcal vaccination
The CAPITA trial demonstrated 75% efficacy against vaccine-type invasive pneumococcal disease and 45% efficacy against pneumococcal pneumonia in adults ≥65. Newer higher-valent vaccines (PCV20, PCV21) cover additional bacterial strains responsible for 30–84% of invasive disease not covered by the older PCV13.
Current recommendation: a single “one-and-done” dose of PCV20 or PCV21 is the preferred approach — broader coverage, one visit.
| Population | Recommendation | Strength |
|---|---|---|
| Adults ≥65 years | PCV20 or PCV21 (single dose) | Strong |
| Adults 19–64 with immunocompromising conditions | PCV20, or PCV15 followed by PPSV23 | Strong |
| Adults 19–64 with chronic heart or lung disease | PCV20 or PCV21 | Strong |
| Previously vaccinated with PCV13 only | PCV20 ≥1 year later, or PPSV23 ≥8 weeks later | Moderate |
RSV vaccination during pregnancy
RSV is the leading cause of hospitalization in infants under 6 months. Maternal RSV vaccination at 32–36 weeks gestation transfers protective antibodies to the baby before birth.
The MATISSE trial demonstrated 82% efficacy against severe RSV-associated lower respiratory tract infections in infants through 90 days of life. A 2024 Cochrane review found maternal RSV vaccination reduced infant RSV hospitalizations by 50% (RR 0.50, 95% CI 0.31–0.82) — 11 fewer hospitalizations per 1,000 infants. The most dramatic impact was in infants 0–2 months: a 56–63% reduction in RSV hospitalizations.
Part 01: What Is the Common Cold? · Part 02: High-Risk Situations (you are here) · Part 03: OTC Medications · Part 04: Nasal Irrigation · Part 05: When to See a Doctor